At the 2017 annual meeting of the American Society of Clinical Oncology, the use of patient reported outcomes took center stage with the release of a landmark randomized clinical trial comparing web-based patient-reported outcomes for symptom (pain, nausea, fatigue) monitoring versus usual care for 766 patients receiving chemotherapy. Use of the tool was associated with a significantly better medial overall survival of 31.2 months compared with 26.0 months in the usual care. Congratulations to principal investigator and MNCM measure development workgroup member, Ethan Basch MD. Read the article here.
MNCM is currently conducting pilot testing of its newly developed measures for Symptom Control During Chemotherapy (SCDC). Submission of data from volunteer test sites from MN Oncology and the University of Minnesota Physicians will occur during July-August and the measure development workgroup will convene later this fall to review results and make recommendations for use.